Specific information about the state of second messengers in drug signaling pathways is key to understanding the mechanism of a drug within the cell. The largest class of drug targets is the G-Protein Coupled Receptor (GPCR) and over 40% of all prescription pharmaceuticals target a GPCR. These proteins are the focus of many drug discovery programs because they are therapeutic targets in a variety of areas including cancer, cardiac disease, diabetes, central nervous system disorders, inflammation, and pain. A critical component of many GPCR signaling pathways is the second messenger, diacylglycerol (DAG), however, there is no commercially available, robust assay for DAG that can be used in either drug screening or basic research applications. The challenge addressed by this proposal is to produce genetically-encoded robust and easy-to-use live cell assay products that can be used to study and to screen for GPCR activation. Phase I of this project demonstrated that it is feasible to produce extremely robust, genetically encoded, fluorescent sensors for DAG. This discovery is significant because despite their great advantages, the impact of genetically encoded assays on drug discovery has been limited because of poor signal to noise and low dynamic range of the response. In Phase II, the prototype sensors developed in Phase 1 will be optimized and packaged for delivery into living cells. These live cell assays will be validated under rigorous high throughput screening conditions to establish suitability for high throughput and in-vivo screening applications.

Public Health Relevance

New assays for biological activity are urgently needed to develop safe and effective drugs that provide better treatment outcomes and improved human health. This proposal addresses the technical challenges associated with using fluorescent live-cell assays and has strong potential to reduce the cost and improve the reliability of drug discovery processes.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
9R44NS082222-02A1
Application #
8648063
Study Section
Special Emphasis Panel (ZRG1-ETTN-G (12))
Program Officer
Fertig, Stephanie
Project Start
2014-01-15
Project End
2015-10-31
Budget Start
2014-01-15
Budget End
2014-12-31
Support Year
2
Fiscal Year
2014
Total Cost
$585,457
Indirect Cost
Name
Montana Molecular, LLC
Department
Type
DUNS #
145280157
City
Bozeman
State
MT
Country
United States
Zip Code
59715
Chen, Xingjuan; Egly, Christian; Riley, Ashley M et al. (2014) PKC-dependent Phosphorylation of the H1 Histamine Receptor Modulates TRPC6 Activity. Cells 3:247-57